SA 16002
Alternative Names: HLIM; SA-16002Latest Information Update: 25 Mar 2021
At a glance
- Originator SAMA Pharmaceuticals
- Class Anti-inflammatories; Antibronchitics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bronchitis
Most Recent Events
- 25 Mar 2021 Discontinued - Phase-III for Bronchitis (In adolescents, In children, In the elderly, In adults) in South Korea (unspecified route) ( SAMA Pharmaceuticals pipeline, March 2021)
- 20 Dec 2018 SAMA Pharmaceuticals initiates enrolment in a phase I trial for Bronchitis in South Korea prior to December 2018
- 29 Nov 2018 Phase-III clinical trials in Bronchitis (In children, In adolescents, In adults, In the elderly) in South Korea (unspecified route) (NCT03827590)